Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab

• Published in: Drug design, development and therapy development and therapy, 2015, Vol.9 (default), p.147-154
• Main Authors: Krupka, Niklas, Baumgart, Daniel C
• Format: Article
• Language: English
• Subjects: Animals; anti-α4β7; Antibodies, Monoclonal, Humanized - chemistry; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Cell Movement - drug effects; Colon; Crohn's disease; Disease control; Drug Design; Drug therapy; FDA approval; Gastrointestinal Agents - chemistry; Gastrointestinal Agents - pharmacology; Gastrointestinal Agents - therapeutic use; Humans; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Intestine; Intolerance; LDP-02; Leukocytes; Leukocytes - drug effects; Methods; MLN-02; MLN0002; Molecular targeted therapy; Patient outcomes; Review; Selectivity; Side effects; Therapeutic applications; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Ulcerative colitis; Vedolizumab
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S50348

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. Here we discuss the clinical trial results of vedolizumab (anti-α4β7, LDP-02, MLN-02, and MLN0002) and its impact on future management of inflammatory bowel disease.